Repurposing antiviral phytochemicals from the leaf extracts of Spondias mombin (Linn) towards the identifcation of potential SARSCOV‑2 inhibitors

dc.contributor.authorBoadu, Akwasi
dc.contributor.authorAgoni, Clement
dc.contributor.authorKarpoormath, Rajshekhar
dc.contributor.authorSoliman, Mahmoud
dc.contributor.authorNlooto, Manimbulu
dc.date.accessioned2024-10-24T06:39:36Z
dc.date.available2024-10-24T06:39:36Z
dc.date.issued2022
dc.descriptionJournal article published in Scientific Reports | (2022) 12:10896en_US
dc.description.abstractSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a pneumonia-like disease with a pattern of acute respiratory symptoms, currently remains a significant public health concern causing tremendous human suffering. Although several approved vaccines exist, vaccine hesitancy, limited vaccine availability, high rate of viral mutation, and the absence of approved drugs account for the persistence of SARS-CoV-2 infections. The investigation of possibly repurposing of phytochemical compounds as therapeutic alternatives has gained momentum due to their reported affordability and minimal toxicity. This study investigated anti-viral phytochemical compounds from ethanolic leaf extracts of Spondias mombin L as potential inhibitor candidates against SARS-CoV-2. We identified Geraniin and 2-O-Cafeoyl-(+)-allohydroxycitric acid as potential SARS-CoV-2 inhibitor candidates targeting the SARS-CoV-2 RNA-dependent polymerase receptor-binding domain (RBD) of SARSCoV-2 viral S-protein and the 3C-like main protease (3CLpro). Geraniin exhibited binding free energy (ΔGbind) of − 25.87 kcal/mol and − 21.74 kcal/mol towards SARS-CoV-2 RNA-dependent polymerase and receptor-binding domain (RBD) of SARS-CoV-2 viral S-protein respectively, whereas 2-O-Cafeoyl(+)-allohydroxycitric acid exhibited a ΔGbind of − 32 kcal/mol towards 3CLpro. Molecular Dynamics simulations indicated a possible interference to the functioning of SARS-CoV-2 targets by the two identified inhibitors. However, further in vitro and in vivo evaluation of these potential SARS-CoV-2 therapeutic inhibitor candidates is needed.en_US
dc.format.extent14 pagesen_US
dc.identifier.urihttp://hdl.handle.net/10386/4704
dc.language.isoenen_US
dc.publisherScientifc Reportsen_US
dc.relation.requiresPDFen_US
dc.subjectAntiviral phytochemicalsen_US
dc.subjectLeaf extractsen_US
dc.subjectSpondias mombin (Linn)en_US
dc.subjectSARSCOV‑2 inhibitorsen_US
dc.subjectRespiratory Syndromeen_US
dc.subjectPneumonia-like diseaseen_US
dc.subjectSARS-CoV-2 infectionsen_US
dc.subject.lcshCOVID-19 (Disease)en_US
dc.subject.lcshRespiratory distress syndromeen_US
dc.subject.lcshMombinen_US
dc.titleRepurposing antiviral phytochemicals from the leaf extracts of Spondias mombin (Linn) towards the identifcation of potential SARSCOV‑2 inhibitorsen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
boadu_repurposing_2022.pdf
Size:
4.4 MB
Format:
Adobe Portable Document Format
Description:
Journal Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
53 B
Format:
Item-specific license agreed upon to submission
Description:

Collections